Hematuria Treatment Market growing at a CAGR of 3.1% from 2025 to 2033

The global hematuria treatment market size was estimated at USD 1,087.3 million in 2024 and is projected to reach USD 1,426.9 million by 2033, growing at a CAGR of 3.1% from 2025 to 2033. The market is driven by urological care and sustained by the growing prevalence of recurrent urinary tract infections, bladder cancer, and urolithiasis, alongside an expanding geriatric population.

Furthermore, rising urinary tract infection (UTI) incidence increases episodic hematuria presentations and empirical antibiotic use, which drives urgent evaluation demand and creates pressure for faster, point-of-care diagnostics. New rapid diagnostics have shortened pathogen identification, directly affecting hematuria treatment pathways by shortening time-to-diagnosis.

Urolithiasis prevalence and symptomatic stone events are important non-neoplastic causes of visible hematuria and often require definitive endourologic care (URS, PCNL) or imaging triage. Although some age-standardised rates have declined, absolute case counts, and new presentations have risen in many regions. It is characterized by symptoms and a high likelihood of recurrence and has created a considerable burden on the healthcare system, especially affecting individuals aged 20 to 54. This indicates substantial age-standardized incidence of stone disease and rising rates in many regions, which raises emergency and elective procedure volumes. Diagnostic cystoscopy remains among the most frequently performed urology procedures, so rising stone and hematuria referrals drive the industry.

Hematuria Treatment Market Report Scope